Aimei Health Technology Co. Ltd Ordinary Share (AFJK)

FairStock Score: 7/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Mr. Market is asking $12.06 for Aimei Health Technology, or about $286.7 million, at the close on 2026-10-26. This is not an operating business in the Graham sense: the company has no significant operations and revenue is n/a in every filed period shown. It is a 2023-vintage shell hoping to merge with or acquire a biopharma, medical technology, diagnostics, or service business. The filed figures show net income of $2.6 million in FY2024 and $1.1 million in FY2025, but the path is uneven: $424,970 in fiscal Q2 2025, $352,019 in fiscal Q3 2025, $45,440 in fiscal Q1 2026, and a loss of $83,144 in fiscal Q2 2026. Trailing free cash flow is -$370,854. FairStock's P/E is 172.31, its Graham Number is $2.00, and the margin of safety is -503.10%; on those calculations the price is far above conservative value. The 7/100 FairStock score and 2/9 Piotroski F-Score suggest thin financial quality, while the Altman Z-Score of 37.13 is less meaningful for a shell with little operating history. FairStock's ROCE is -1.39%, and profit growth is -119.56%. There is no demonstrated competitive moat—only the option value of a future deal. The Lynch category is none because there are only two years of filed results. I can admire the search for a good acquisition, but I cannot call this a bargain without a target, durable earnings, or a price closer to that conservative value.

In plain English: Aimei Health Technology is a shell company with no significant operations; it plans to merge with or buy a health-care business. Its filed results show small profits in FY2024 and FY2025, but the latest filed quarter had a loss, and it is spending more cash than it brings in. At $12.06, the price looks very expensive compared with its tiny earnings and a conservative estimate of its value.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer